Atara Biotherapeutics Inc ATRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atara Biotherapeutics Announces Changes to Its Board of Directors
-
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
-
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
-
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
-
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
-
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
-
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Trading Information
- Previous Close Price
- $9.95
- Day Range
- $9.36–10.06
- 52-Week Range
- $3.92–19.15
- Bid/Ask
- $9.35 / $10.80
- Shares Outstanding
- 9.01M
- Market Cap
- $87.94M
- Volume/Avg
- 66,882 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 2.51
- Price/Sales
- 6.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.atarabio.com
Valuation
|
Metric
|
ATRA
|
|---|---|
Price/Earnings (Normalized) | 2.51 |
Price/Book Value | — |
Price/Sales | 6.00 |
Price/Cash Flow | — |
Price/Earnings
ATRA
Financial Strength
|
Metric
|
ATRA
|
|---|---|
Quick Ratio | 1.48 |
Current Ratio | 2.16 |
Interest Coverage | −1.76 |
Quick Ratio
ATRA
Profitability
|
Metric
|
ATRA
|
|---|---|
Return on Assets (Normalized) | −11.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|GwRFTB$ | LOCK|@Dm?% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&>$W!& | LOCK|#hF>v | $70B | |||
| argenx SE ADR
ARGX
| LOCK|%BXWS# | LOCK|d#L | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%c>nXpL | LOCK|Xd!J | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<WwQt@ | LOCK|mb | $36B | |||
| Moderna Inc
MRNA
| LOCK|PNYR?@H | LOCK|y$v | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|B$K@W<x | LOCK|^#B< | $25B | |||
| Incyte Corp
INCY
| LOCK|!$Y!g## | LOCK|$> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?dZqC% | LOCK|<l | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|j$w&Q^ | LOCK|QBf | $17B |
United States